Innate Pharma : Lacutamab : suspension clinique partielle, résultats TELLOMAK toujours attendus au T4 2023
>Suspension de la FDA à la suite d’une suspicion d’effet indésirable grave - Innate Pharma fournit ce matin un update sur son programme clinique lacutamab actuellement en phase 2 (TELLOMAK) dans le traitement du syndrome de Sézary et du mycosis fongoïde et en phase 1b dans les lymphomes T périphériques. La société communique à cette occasion la décision de la FDA d’une suspension clinique partielle et d’une suspension du recrutement de nouveaux patients des essais en ...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.